Effect of Diflunisal in Patients with Transthyretin Cardiomyopathy: A Pilot Study.

ABSTRACT: Background: ATTR-CM is becoming more prevalent, and disease-modifying therapy has been investigated in recent years with promising results. Diflunisal has shown TTR-stabilizing properties assessed by biomarkers and echocardiography, but there are no trials addressing the evolution of morphological changes with CMR. Methods and Results: AMILCA-DIFLU is an exploratory pilot study prospective, single-center, non-randomized, open-label clinical trial. Patients diagnosed with ATTR-CM underwent clinical, functional, biochemical and imaging assessment before and one year after diflunisal therapy initiation. Of the twelve ATTR-CM patients included, only nine patients completed treatment and study protocol in 12 months. To increase the sample size, we included seven real-world patient

SUBMITTER: Camblor Blasco A 

PROVIDER: S-EPMC11396251 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature